MYCOPHENOLATE MOFETIL SHARED CARE PROTOCOL

Your patient has now been on mycophenolate for at least 12 months, at a dose detailed in the most recent clinic letter, and has received blood test monitoring from the Rheumatology department which is stable. We would now be grateful if your practice would take over the responsibility for:

- Prescribing the mycophenolate
- Performing the blood tests and monitoring the results (if your practice is signed up to shared care LES)

We would be grateful if you would fax / post back the attached sheet to indicate acceptance of the shared care agreement.

If patients fail to attend for their monitoring, we would recommend contacting them to arrange one further monitoring appointment but thereafter to stop prescribing their treatment until the monitoring requirements have been met.

The patient carries a hand held monitoring book, which has been kept up to date by the Rheumatology department, and/or GP prescriber, and contains patient information.

Important Information:

- Repeat prescriptions should be retained separately (i.e. highlighted as different to all other repeat prescriptions), so the GP prescriber can ensure monitoring has been undertaken prior to signing and issuing to patient
- Alcohol intake should be limited to nationally recommended levels.
- Mycophenolate is contraindicated in pregnancy and when breastfeeding and contraception is therefore advised in patients who are sexually active. Both men and women should be advised to stop Mycophenolate at least 3 months before a planned pregnancy.
- Live vaccines should not be given
- Annual flu jab is advised recommended (to be given by GP practice)
- Avoid exposure to chickenpox and shingles. If infection develops it should be treated aggressively with antiviral medication and Rheumatology dept can be contacted for advice
- Side effects include: Headache / dizziness / oral ulceration / rash / nausea / diarrhoea / alopecia – drug continuation depends on severity and patient wishes

Treatment is usually started at a dose of 500mg twice daily and increased to a maximum of 1.5g twice daily according to clinical response. If eGFR < 30, starting dose of 250mg bd is used.
Monitoring schedule:

- FBC/ U&E / LFT / CRP
  - weekly for first 4 weeks of treatment (consultant responsibility)
  - then fortnightly for 8 weeks (consultant responsibility)
  - monthly for the rest of the first year (consultant responsibility)
- 3 monthly thereafter unless dose changes (GP practice responsibility)
- If dose increase: additional FBC/U&E/LFT at 2 & 4 weeks
- Results to be entered into hand held monitoring booklet

IF:

- WCC < 3.5 x 10^9/l
- Neutrophils < 1.8 x 10^9/l
- Platelets < 150 x 10^9/l
- AST or ALT > 100

OR: Severe sore throat / Oral Ulceration / Fever / Rash

Stop medication and contact Rheumatology service.

If CRP elevated (>25) and patient symptomatic, inform Rheumatology department. If CRP suddenly elevated without significant change to joint symptoms assess patient for infection. Occasionally patients run a persistently high CRP without joint symptoms – this will usually be flagged up in clinic letters.

Mycophenolate can cause gastrointestinal bleeding. STOP if coffee ground vomit, haematemesis or melaena and seek immediate advice.

Patients should stop Mycophenolate if they have significant infection requiring antibiotics (or chickenpox / shingles), and restart once infection treated.

Department Contact details:

Fax: 01709 424276
Telephone Helpline: 01709 424739

Consultants:
  Dr James Maxwell 01709 424156
  Dr Fiona Fawthrop 01709 424275
  Dr Gillian Smith 01709 424169

Nurse Specialists:
  Sister Sue Elsey + Sister Hayley Coop – Bleep 079 via Switch

Specialist Registrar: available on bleep 101 via Switchboard
Rheumatology Mycophenolate Shared Care Monitoring Agreement for Transfer of Prescribing and Monitoring from Hospital to Primary Care

Patient: ................................

Consultant: ..............................

Name of General Practitioner: Dr. .............................................................

Name of GP Practice: ..........................................................

Please initial each box as appropriate:

I am in agreement that from ……. /…… / 20…… the practice will take over the prescribing of Mycophenolate for the above patient in accordance with the shared care guidelines which are attached.

☐ The practice is happy to take on the blood test monitoring according to the schedule above, and will ensure that this patient’s Shared Care Monitoring booklet is updated soon after the results become available.

I also confirm that I will take appropriate action, in accordance with the above-mentioned Guidelines in the event of abnormal blood tests or other adverse reactions, and will inform the patient’s Rheumatologist if I advise the patient to stop their DMARD medication.

☐ I am aware that all of the Consultant Rheumatologists are happy to be contacted about their patients via their secretaries if there are any concerns.

GP Signature ................................. Print Name .................................

Date .................................

Please FAX Once Complete to 01709 424276